PRE-CLINICAL RESEARCH
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers, MD, PhD*, ,*,
José P.S. Henriques, MD,
Dominique P.V. de Kleijn, PhD*,||,
J. Hans DeVries, MD, PhD ,
Hans Kemperman, PhD ,
Paul Steendijk, PhD¶,
Cees W.J. Verlaan, BSc*,
Marjolein Kerver, MSc*,
Jan J. Piek, MD, PhD, FACC,
Pieter A. Doevendans, MD, PhD*,
Gerard Pasterkamp, MD, PhD* and
Imo E. Hoefer, MD, PhD*
* Department of Cardiology, University of Medical Center Utrecht, UMC Utrecht, the Netherlands
Department of Clinical Chemistry and Hematology, University of Medical Center Utrecht, Utrecht, the Netherlands
Department of Cardiology, Academic Medical Center, AMC Amsterdam, the Netherlands
Department of Internal Medicine, Academic Medical Center, Amsterdam, Amsterdam, the Netherlands
|| Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
¶ Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
Manuscript received June 23, 2008;
revised manuscript received October 20, 2008,
accepted October 20, 2008.
* Reprint requests and correspondence: Dr. Leo Timmers, Laboratory of Experimental Cardiology, University Medical Center Utrecht, Room number G02.523, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands (Email: l.timmers{at}umcutrecht.nl).
Objectives: This study sought to examine whether exenatide is capable of reducing myocardial infarct size.
Background: Exenatide is a glucagon-like peptide (GLP)-1 analogue with insulinotropic and insulinomimetic properties. Because insulin and GLP-1 have been described as reducing apoptosis, exenatide might confer cardioprotection after acute myocardial infarction (MI).
Methods: Pigs were randomized to exenatide or phosphate-buffered saline (PBS) treatment after 75 min of coronary artery ligation and subsequent reperfusion. Infarct size was assessed with Evans Blue (Sigma-Aldrich, St. Louis, Missouri) and triphenyltetrazolium chloride. Cardiac function was measured with epicardial ultrasound and conductance catheter-based pressure-volume loops. Western blotting, histology, and activity assays were performed to determine markers of apoptosis/survival and oxidative stress.
Results: Exenatide reduced myocardial infarct size (32.7 ± 6.4% vs. 53.6 ± 3.9%; p = 0.031) and prevented deterioration of systolic and diastolic cardiac function (systolic wall thickening: 47.3 ± 6.3% vs. 8.1 ± 1.9%, p < 0.001; myocardial stiffness: 0.12 ± 0.06 mm Hg/ml vs. 0.22 ± 0.07 mm Hg/ml; p = 0.004). After exenatide treatment, myocardial phosphorylated Akt and Bcl-2 expression levels were higher compared with those after PBS treatment, and active caspase 3 expression was lower. In addition, fewer cells were terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling-positive. In addition, nuclear oxidative stress as assessed with an 8-hydroxydeoxyguanosine staining was reduced in the exenatide treatment arm, and superoxide dismutase activity and catalase activity were increased. Serum insulin levels increased after exenatide treatment, without affecting glucose levels.
Conclusions: These data identify exenatide as a potentially effective compound to reduce infarct size in adjunction to reperfusion therapy in patients with acute MI.
Key Words: exenatide • glucagon-like peptide 1 • myocardial infarction • reperfusion
|
Abbreviations and Acronyms
| | AAR = area at risk | | ED = end-diastole/diastolic | | ES = end-systole/systolic | | GLP = glucagon-like peptide | | I/R = ischemia and reperfusion | | LCx = left circumflex coronary artery | | LV = left ventricle | | MI = myocardial infarction | | OHdG = hydroxydeoxyguanosine | | pAkt = phosphorylated Akt | | PBS = phosphate-buffered saline | | STEMI = ST-segment elevation myocardial infarction | | TUNEL = terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling |
|
Related Articles
-
Lizard Spit and Reperfusion Injury
- Ian G. Webb, Rupert Williams, and Michael S. Marber
J. Am. Coll. Cardiol. 2009 53: 511-513.
[Full Text]
[PDF]
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A26.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. J. Ha, W. Kim, J. S. Woo, J. B. Kim, S. J. Kim, W.-S. Kim, M. K. Kim, X. W. Cheng, and K. S. Kim
Preventive Effects of Exenatide on Endothelial Dysfunction Induced by Ischemia-Reperfusion Injury via KATP Channels
Arterioscler Thromb Vasc Biol,
February 1, 2012;
32(2):
474 - 480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chaudhuri, H. Ghanim, M. Vora, C. L. Sia, K. Korzeniewski, S. Dhindsa, A. Makdissi, and P. Dandona
Exenatide Exerts a Potent Antiinflammatory Effect
J. Clin. Endocrinol. Metab.,
January 1, 2012;
97(1):
198 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Hausenloy and D. M. Yellon
Taking lizard saliva to heart
Eur. Heart J.,
October 11, 2011;
(2011)
ehr382v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lonborg, N. Vejlstrup, H. Kelbaek, H. E. Botker, W. Y. Kim, A. B. Mathiasen, E. Jorgensen, S. Helqvist, K. Saunamaki, P. Clemmensen, et al.
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Eur. Heart J.,
September 14, 2011;
(2011)
ehr309v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sussman, M. Volkers, K. Fischer, B. Bailey, C. T. Cottage, S. Din, N. Gude, D. Avitabile, R. Alvarez, B. Sundararaman, et al.
Myocardial AKT: The Omnipresent Nexus
Physiol Rev,
July 1, 2011;
91(3):
1023 - 1070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cernea and I. Raz
Therapy in the Early Stage: Incretins
Diabetes Care,
May 1, 2011;
34(Supplement_2):
S264 - S271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ravassa, A. Zudaire, R. D. Carr, and J. Diez
Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes
Am J Physiol Heart Circ Physiol,
April 1, 2011;
300(4):
H1361 - H1372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. De Caterina, R. Madonna, H. Sourij, and T. Wascher
Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options
Eur. Heart J.,
July 1, 2010;
31(13):
1557 - 1564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jaffe, A. Dick, and B. H. Strauss
Prevention and Treatment of Microvascular Obstruction-Related Myocardial Injury and Coronary No-Reflow Following Percutaneous Coronary Intervention: A Systematic Approach
J. Am. Coll. Cardiol. Intv.,
July 1, 2010;
3(7):
695 - 704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ye, K. T. Keyes, C. Zhang, J. R. Perez-Polo, Y. Lin, and Y. Birnbaum
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
Am J Physiol Heart Circ Physiol,
May 1, 2010;
298(5):
H1454 - H1465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. Murthy, R. C. S. Hilaire, D. B. Casey, A. M. Badejo, J. McGee, D. B. McNamara, P. J. Kadowitz, and V. A. Fonseca
The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats
Diabetes and Vascular Disease Research,
April 1, 2010;
7(2):
138 - 144.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. A. Read, F. Z. Khan, P. M. Heck, S. P. Hoole, and D. P. Dutka
DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
Circ Cardiovasc Imaging,
March 1, 2010;
3(2):
195 - 201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Drucker, S. I. Sherman, F. S. Gorelick, R. M. Bergenstal, R. S. Sherwin, and J. B. Buse
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Diabetes Care,
February 1, 2010;
33(2):
428 - 433.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Burchfield, J.-W. Dong, Y. Sakata, F. Gao, H.-P. Tzeng, V. K. Topkara, M. L. Entman, N. Sivasubramanian, and D. L. Mann
The Cytoprotective Effects of Tumor Necrosis Factor Are Conveyed Through Tumor Necrosis Factor Receptor-Associated Factor 2 in the Heart
Circ Heart Fail,
January 1, 2010;
3(1):
157 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Garcia-Dorado, M. Ruiz-Meana, and H. M. Piper
Lethal reperfusion injury in acute myocardial infarction: facts and unresolved issues
Cardiovasc Res,
July 15, 2009;
83(2):
165 - 168.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. G. Webb, R. Williams, and M. S. Marber
Lizard Spit and Reperfusion Injury
J. Am. Coll. Cardiol.,
February 10, 2009;
53(6):
511 - 513.
[Full Text]
[PDF]
|
|
|
|
